|Bid||4.1600 x 3200|
|Ask||4.2000 x 3200|
|Day's Range||4.1600 - 4.3200|
|52 Week Range||2.0800 - 6.3130|
|Beta (3Y Monthly)||2.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ADMA Biologics, a late-stage biotechnology, will add new jobs to its Boca Raton campus. The Business Development Board of Palm Beach County on Monday announced that the Ramsey, New Jersey-based company (Nasdaq: ADMA) will increase its number of workers there to 350 with help from the economic development agency. It currently has 250 workers in Boca Raton.
Adam Grossman became the CEO of ADMA Biologics, Inc. (NASDAQ:ADMA) in 2011. This report will, first, examine the CEO...
A look at the shareholders of ADMA Biologics, Inc. (NASDAQ:ADMA) can tell us which group is most powerful. Generally...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
After years of struggle, ADMA Biologics (ADMA) appears at last to be poised for bigger things. The Food and Drug Administration's recent approval of two of its intravenous immune globulin (IVIG) drug products, Asceniv and Bivigam, has put this stock back on the radar. Combined with a timely capital raise, ADMA's two new products should set it up for an impressive breakout in the second half of 2019.
Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.
President and CEO of Adma Biologics Inc (NASDAQ:ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share.
The Ramsey, New Jersey-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring gains, came to 31 cents per share. The results topped Wall Street expectations. The average ...
Why ADMA Biologics Stock Soared Yesterday(Continued from Prior Part)Revenue growth estimates ADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest
Why ADMA Biologics Stock Soared YesterdayShare price movements Yesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price, 143.27% higher than its 52-week low of $2.08, and 27.30% lower than its
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
ADMA announced Monday after the market close that the FDA approved its Asceniv, a novel, patented, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease, or PIDD, in adults and adolescents ages 12-17. PIDD is a collective name for more than 300 diseases that occur due to defects in the body's immune system, invariably manifesting as acute or recurrent infections. Asceniv is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends the source plasma and plasma from donors testing using its proprietary microneutralization assay.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
The Ramsey, New Jersey-based company said it had a loss of 39 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said. The FDA decision comes more than two years after the drug's previous owner suspended its production. Bivigam is a treatment given through the veins for patients with primary humoral immunodeficiency, a condition that compromises the body's ability to fight infections.
Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...